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Because of the increasing clinical demand, research and development 
in bone tissue engineering has advanced a lot in the past few years. 
Osteogenesis is one of the key components of bone development as 
well as regeneration. Osteogenic cultures of human embryonic stem 
cells (hESCs) play an important role in the research of therapies for 
bone defects. At present stage, it is a daunting task to find out the 
regulating mechanisms that controls the process of in-vivo osteogenic 
differentiation.  
Use of hESCs and GFP transfected hESC for the future in-vivo study 
not only helps us to detect hESC from the tissue of the host after 
transplanting but also helps us to understand the development of 
osteoblast cells that constitute the bone and its functions. However, 
one of the prerequisites for using GFP transfected hESCs derived 
osteoblasts for in-vivo studies is that there is no difference between the 
characteristics of GFP transfected hESCs and normal hESC-derived 
osteogenic cells. In other words, GFP transfection should not influence 
the process of osteogenic differentiation of hESCs. However, the 
influence of fluorescent protein transfection on hESC osteogenesis still 
remains unknown. Therefore, the osteogenic differentiation potential of 
hESCs and GFP expressing hESCs has been investigated in this study. 
In this study, GFP was transfected into H1 and H9 hESCs lines in a 
non-viral approach. The GFP-transfected and non-transfected H1 and 
 viii 
H9 were cultured in osteogenic media for 21 days. The osteogenesis of 
H1, H1GFP+, H9 and H9GFP+ were evaluated and compared by 
histochemical staining, immunocytochemical staining and real-time 
polymerase chain reaction. The expression of osteogenesis markers 
and osteoblast-specific markers indicated that the osteogenesis of 
H1GFP+ and H9GFP+ were not affected by GFP transfection. The results 
have demonstrated the feasibility of lineage tracking via tagging hESCs 
with GFP in the hESCs osteogenesis research. 
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Chapter I  









1.1       Bone tissue engineering 
 
1.1.1    Fundamentals of Bone 
  
Bones are important living tissue in our body. They provide structural 
support and protect internal organs. Bone is a highly vascular, 
mineralized connective tissue with the ability to undergo repair and 
regeneration without any evidence of scar tissue. Mature bone is 
composed of two layers: 1) a hard outer layer, called cortical (compact) 
bone which is compact, dense and tough; 2) a spongy inner layer, 
called trabecular (cancellous) bone which is made up of a  network of 
bony trabecular and hence is less dense than the cortical bone [1].  
 
The cellular component of the bone is composed of osteoblasts, 
osteocytes and osteoclasts. Osteoblasts are the bone-forming cells 
that line the inner and outer layers of bone & bone trabecular; while the 
osteocytes are the resting cells that reside inside the spaces called 
lacunae and canaliculi; and the osteoclasts are the bone-resorbing 
cells that lie within concavities called Howship’s lacunae. These three 
bone cells maintain the bone in a dynamic cycle of resorption and 
formation. 
 
Bone matrix is composed of inorganic mineralized component and 
organic proteinaceous component. The organic component is 
comprised predominantly of type I collagen (~94%) and 
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noncollagenous proteins. The hardness and rigidity of bone is due to 
the presence of mineral salt in the matrix, which is a crystalline 
complex of calcium and phosphate (hydroxyapatite). Calcified bone 
contains about 25% organic matrix (2-5% of which are cells), 5% water 
and 70% inorganic mineral (hydroxyapatite)[1]. 
 
1.1.2    Bone grafting and clinical needs 
 
Bone tissue defects caused by injury or disease are significant 
problems in orthopedic surgery. Repairing or replacing damaged or 
diseased tissue is the ultimate goal of tissue engineering. Pioneering 
attempts at cellular therapy in bone regeneration have yielded good 
results, especially regarding the durability of the repair [2, 3]. Since 
then various modes of delivery and retention of cells implanted into the 
defect site have been investigated in the past few decades.  
 
Clinical application of bone tissue engineering: Management of large 
bone defects is critical issue, which could occur after massive traumatic 
bone loss or resection of a primary tumor of the bone. Bone grafting is 
commonly employed to occupy the large defect and enhance the bone 
regeneration. Autologous bone grafting is considered as the ‘gold 
standard’ due to its osteoinductive, osteogenic, osteoconductive and 
non-immuogenic/ histocompatible properties [4]. However, their use is 
hampered due to additional invasive surgery and morbidity/ 
complications associated with it and the limited amount of bone that 
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could be harvested [4, 5]. Allogenic bone grafts and demineralized 
bone matrix though overcome the limitations of autologous bone grafts, 
do not have osteogenic ability and have a lower osteoinductive and 
osteoconductive properties [6]. As an alternative allograft and bone 
graft substitutes are widely used. These biomaterials provide good 
mechanical support and 3D architecture. However, most of these 
biomaterials lack remodeling and sufficient tissue formation around the 
biomaterials due to poor interaction with the host tissue leading to 
failure rates of up to 30% [7, 8]. Hence, insufficient bone healing 
remains a clinical challenge and tissue engineered bone constructs 
have the potential to alleviate such a demand for these materials [9]. 
Bone grafts for injuries, tumors, infections and degenerative diseases 
are expensive. Statistics can explain the enormity of this problem. Each 
year, in the United States alone, there are approximately 15 million 
fractures ($45bil); 1.6 million patients with trauma leading to hospital 
admission ($27bil); 2 million osteoporotic fractures  ($24bil); 500,000 
knee, 350,000 hip replacements, and 90,000 revision arthroplasty 
procedures ($30bil); 300,000 spinal fusions, 20,000 revision spine 
fusions ($18bil); 2,400 primary bone malignancies; and 4,500 benign 
tumors ($100mil). Collectively, there are approximately 1.6 million bone 
grafts being performed annually in the U.S. [10] 
 
1.1.3 Tissue engineering 
 
 5 
Since the concept of tissue engineering was first introduced in 1984, 
the field of regenerative medicine have been developing rapidly [11]. 
The concept of tissue engineering is defined as follows: Tissue 
engineering is “an interdisciplinary research that combines the 
principles of engineering and life science, trying to develop biological 
substitutes that restore, maintain or improve tissue function”[12].  
 
The goal of tissue engineering is to construct the three-dimensional 
complex tissue composed of cells and biological materials, i.e. viable 
living body tissue, in order to reconstruct and restore the form, 
structure and function of diseased or damaged tissue, and permanently 
substitute the original tissue, so as to achieve the goal of repairing and 
restoring function. Similarly, bone tissue engineering aims at repairing 
and/or reconstructing bone tissue defects or damages by applying the 
basic principles of tissue engineering. One emphasis of bone tissue 
engineering research is to devise effective method to deliver skeletal 
stem or progenitor cells to repair bone. Generally speaking, bone 
tissue engineering includes three main factors: biomaterials (scaffolds), 
cells and biomolecules [13]. 
 
1.2    Bone regeneration and stem cells 
 
Currently, there are four ways of regenerating new tissue. The first 
modality is through cellular therapy by directly injecting suspended 
cells and/or growth factors into the damaged area. The second method 
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involves implantation of a scaffold or matrix into the body and depends 
on the host cells to gradually grow into it. The third approach involves, 
injection of bone promoting growth factors or biomolecules that would 
trigger recruit and bone formation by the host cells. The fourth 
approach is a combination of one or more of the above mentioned 
methods wherein the scaffold or matrix with cells and/or biomolecules 
implanted into the body. [14] 
 
Generally speaking, it is commonly agreed that living osteoprogenitor 
cells or osteoblast-like cells, effective scaffolds and regulating factors 
are key to bone regeneration. Although the materials for retaining cells 
are essential to the composition of high quality constructs, choosing an 
appropriate cell source for the research of bone tissue engineering is 
also key in the research and application of osteogenesis. Cells derived 
from adipose tissue, cord blood, periostium, amniotic fluids, circulating 
skeletal cells, bone marrow stromal cells, trabecular bone cells, dental 
pulp as well as cells from almost every connective tissue, have been 
shown to have potential for osteoblast differentiation in-vitro. However, 
being able to  differentiate in-vitro may not be the best proof to testify 
cell populations’  in-vivo behavior [10]. 
 
Figure 1.1 Stem cell-based bone tissue engineering (Jeong Min Seong, 




In the past, bone marrow served as the most common cell source for 
bone regeneration. In recent years, researches have searched for 
alternative sources, that include embryonic stem cells and induced 
pluripotent stem cells [15]. To date, it is worth to note that stem cells 
are one of the most promising cells for bone tissue engineering. The 
potential of stem cells in bone tissue engineering will be introduced in 
detail in the following part.   
 
1.2.1 Stem cells 
 
The term “stem cells” refers to undifferentiated cells which have 
potential to develop into many different cell types in the body and have 
the ability of self-renewal for long period without limit to replenish other 
cells [16]. In addition, when stem cells divides, at least one of the 
daughter cells retains the pluripotency and it can be recovered after 
long periods of inactivity. Stem cells can be derived from embryo, fetus 
or adult. Self-renewal, multi-lineage differentiation and unspecialization 
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are three general properties which distinguish stem cells from other 
types of cells in the body [17]. 
 
To date, scientists categorize stem cells into three types: adult stem 
cells, embryonic stem cells and induced pluripotent stem cells (iPS). 
The iPS cells have been generated from somatic cells by 
reprogramming technologies in recent years [18, 19]. The iPS cells, as 
a candidate of novel type stem cells have provided great potential for 
regenerative medicine. 
 
 1.2.1.1    Adult stem cells 
 
Adult stem cells are the original cells which exist in normal tissues and 
organs and have not terminally differentiated. These cells have the 
potential for differentiation into multiple tissue cells. When tissues or 
organs functions normally, these cells usually remain in a dormant 
state.  Under circumstances of organ damage, injury etc., these 
dormant adult stem cells are able to differentiate into somatic cells to 
help supplement or repair the organ, and then achieve self-repair or 
self-renewal of the organ. These processes keep tissues and organs in 
a constant and dynamic balance of growth and wane. Early scientists 
used to believe that adult stem cells only exist in the tissues and 
organs which are capable of self-renewal and self-repair. For example, 
hematopoietic stem cells can be cultured in hematopoietic system. As 
later researchers probed deeper into this field, researchers found that 
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those tissues deemed as not capable of regeneration by traditional 
medical science also contain stem cells. [20-23] 
 
Adult stem cells are characterized by three salient features; 1) Potential 
to differentiate into certain cell groups, 2) These cells are comparatively 
easy to obtain. Because these cells are not related with embryos, there 
are fewer controversies about research on these cells, 3) Autologous 
use of these cells is believed to lack issues related to transplant 
rejection. [24]. However, these cells are rare especially with increasing 
age and presence of co-morbid diseases. 
 
The research on the adult stem cells originated from research on 
hematopoietic stem cells (HSC) in 1960s. In 1978, the first 
hematopoietic stem cell was introduced in cord blood, giving hopes for 
treating certain blood and immune diseases such as leukemia and 
anemia [20]. After the discovery of HSCs in bone marrow, 
Mesenchymal stem cells (MSCs) have been isolated from bone 
marrow, adipose tissue, periosteum and the human umbilical cord. 
These cells have the potential of differentiation into osteoblasts. [25, 
26]. Utilizing MSCs for bone tissue engineering has various 
advantages that include their ability to improve the healing of bone 
fractures, autologous cellular therapy, and in-vitro expansion. However, 
the self-renewal and proliferative capacity is limited, the purifying 
process is difficult and the differentiation potential reduces gradually 
with age. These constraints limit the application of MSCs.  
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Many types of adult stem cells were found in various tissues than once 
thought possible. Until recently, neural stem cells, olfactory adult stem 
cells, mammary stem cells, adipose-derived stem (AdSCs) cells and 
dental pulp stem cells have been isolated from different tissues 
respectively during past decades [27, 28]. Many of these stem cells 
can differentiate into specialized cell types under appropriate culture 
conditions [29, 30]. 
 
Although many breakthroughs have been achieved in the research of 
adult stem cells, there is still a long way to go before the findings can 
be applied in clinical practice. However, in-vitro culture of MSCs is 
reported to be associated with gradual loss in their potency and 
senescence [31-33]. There have been attempts to improve these 
issues by growth factor supplementation [34], low oxygen tension [35], 
and the use of heparan sulphate [36]. However, the optimal culture 
conditions for these cells need to be established.  
 
1.2.1.2    Embryonic stem cells 
 
In 1981, Martin Evans and Matthew Kaufman from University of 
Cambridge and Gail R. Martin from University of California first isolated 
and derived embryonic stem cells (ESC) from mouse embryos. They 
for first time proved that embryonic stem cells are pluripotent and 
established a standard culture conditions for culturing mouse ESC in-
vitro [37, 38]. 
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ESCs are obtained by isolating them from the inner cell mass of 
blastocyst of 4 to 5-day old embryo which is fertilized in-vitro.  
Pluripotency of early embryonic stem cells are characterized by three 
prominent features: pluripotency, self-renewal and chimera formation.  
 
1.2.1.2.1   Human embryonic stem cells 
 
The first human embryonic stem cell (hESCs) was demonstrated in 
1998. James Thomson and colleagues first derived embryonic stem 
cells from human blastocysts [39]. Since, then various hESC lines have 
been created and their potential to differentiate in-vitro into various 
somatic cells has been investigated.  
 
hESCs due to their ability to be expanded exponentially and 
differentiation to various cell lineages are desirable candidates for 
tissue regeneration and hold great promise for future scientific studies 
and clinical applications. In recent years, numerous reports have been 
published on generation of osteoprogenitors/ osteoblast-like cells from 
hESCs [40-50]. However, there are also certain issues regarding the 
clinical application of hESCs, such as safety concerns, immune 
rejection and ethical problems. 
 
1.2.1.2.2   Characterization of human embryonic stem cells 
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Generally, it is considered that hESC cells are characterized with 
expression of cell markers TRA1-60, TRA1-81, SSEA3, SSEA4, 
GTCM2, OCT4, Rex1, TGT343, Nanog and high levels of telomerase 
activity. Under in-vitro and in-vivo conditions, hESCs show the potential 
for differentiation to cells of the three germ layers. When being injected 
into severe combined immunodeficient (SCID) mice, they exhibit the 
ability to form teratoma which is a major clinical concern for clinical 
application of hESC-derived progenies.  
 
As a matter of fact, each hESC cell line has a distinct expression profile 
[51]. For instance, certain cell lines cannot form teratoma after being 
injected into SCID mice, while teratoma formation is generally deemed 
as one of the features of ES cells [52]. In the process of spontaneous 
differentiation, different cell lines lead to different cell types [53]. 
Further studies on individual characterization of deposited hESC cell 
lines are possible and scientists can choose the most appropriate 
hESC cell line for their experiments. 
 
1.2.1.2.3   Application of human embryonic stem cells 
 
The usefulness of hESCs is highlighted by the recent approvals by U.S. 
Food and Drug Administration (FDA) for Phase I/II clinical trials on the 
use of hESCs. Though Geron pulled out of the clinical trial for financial 
reasons, Advanced Cell Technologies have shown positive progress in 
the use of using hESC derived retinal epithelial pigment cells in the 
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treatment of Stargadt’s Macular Dystrophy and age related macular 
degeneration. 
Overall potential of hESCs include the following: 
- Development and gene control of human tissue, organs and body  
- Delivery of gene and protein for cell based therapy  
- Regenerative medicine  
- Assessment of human relevant function and toxicity/safety for 
therapies, drugs, food, chemicals, materials and techniques  
- Human relevant environment analysis of water, soil, air, 
natural/artificial and chemical/physical products and techniques  
- Study of pathogen, disease and prevention  
 
1.2.1.2.4   H1 and H9 cell linage 
 
The world’s first human embryonic stem cell lines were created at 
University of Wisconsin, Madison in 1998. The patents that govern 
embryonic stem cell technology are held by the Wisconsin Alumni 
Research Foundation, which is a private and non-profit organization of 
the UW-Madison. 
 
The H1 and H9 hESCs line used in this study were purchased from the 
WiCell Research Institute Inc. according to Agreement No.04-W094, 
Madison, Wisc., USA.  WiCell Inc. is a nonprofit research institute, 
which was established in 1999 and registered on the National Institute 
of Health (NIH) stem cell registry. This institute has been approved by 
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the U.S. Government to carry out stem cell research sponsored by 
government-related research funding. The institute is dedicated to 
promoting and facilitating studies on human pluripotent stem cells 
through standardized research protocols, creating and distributing cell 
lines, as well as supporting basic research and researchers on the 
stem cell therapeutic theories and practices. 
 
In this study, hESC H1 and H9 line were cultured and propagated in 
line with the strict requirements prescribed by the Wicell protocols. 
 
1.2.1.3     Induced pluripotent stem cells (iPSCs) 
 
The third major stem cell type is the induced pluripotent stem cells, 
normally abbreviated as iPS cells or iPSCs. iPSCs refers to a type of 
pluripotent stem cell derived from a non-pluripotent cell, typically an 
adult somatic cell. Researchers obtain iPSCs by artificially introducing 
viral factors or other means to induce forced expression of certain 
genes.  
 
iPSCs share many characteristics with human embryonic stem cells, 
such as similar morphology and growth properties, pluripotency, 
differentiation towards three germ layers and teratoma formation. To 
date, expression of stem cell genes and proteins, chromatin 
methylation patterns, doubling time, embryoid body formation, teratoma 
formation, plasticity and differentiation potential are all investigated 
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comparing with normal pluripotent stem cells. In addition, restoring full 
pluripotency in somatic cells as exhibited by ESCs is still being 
assessed. In 2006, the team of Professor Shinya Yamanaka at Kyoto 
University first produced iPSCs from mouse embryonic fibroblasts. 
They retrovirally transfected four important pluripotent characterization 
genes, Oct-3/4, SOX2, c-Myc and Klf4 into the mouse cell and 
converting them into pluripotent stem cell [54]. In 2007, two 
independent teams led by Shinya Yamanaka and James Thomason 
introduced iPSCs from human adult somatic cells respectively by using 
different protocols [18]. After Yamanaka's initial success in 
reprogramming mouse cells, many groups used the same strategy to 
generate human iPS cells. The emergence of the iPS cell technology 
holds great promises for life science research and therapeutic 
applications. However, before iPSCs could be applied in clinical 
practice, issues related to genetic health and teratoma formation needs 
to be addressed. This strategy has many limitations on clinic 
applications. For example, random insertion of retrovirus contains 
potential risks, for some transcription factors themselves are proto-
oncogenes, the transfer of which may result in cancerous cells. To 
avoid such risks, in 2008, Stadtfeld team reported that they used an 
adenovirus as an carrier to transport the four genes successfully to 
obtain iPSCs without combination of its own genes [55]. Later, 
Yamanaka‘s group reported that they found a new total viral free 
system in making iPSCs [56]. This system increases the potential use 
of iPSCs in human diseases. However, low efficiency is the weakness 
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of this method. Research in 2009 demonstrated that it is possible to 
generate iPSCs without genetically changing the adult cell. Certain 
proteins were channeled into the cells by poly-arginine anchors 
repeatedly, and it was reported to be sufficient to induce pluripotency 
[57]. In 2011, iPSCs were used in periodontal regeneration for the first 
time [58]. The research manifested that iPSCs combined with low 
inflammatory response of silk fibroin and enamel matrix derivatives 
(EMD) promote cementum, periodontal tissue regeneration. 
 
The difference between the three types of stem cells is listed below: 
Figure 1.2   Difference between stem cells 
 
 
In summary, through the above detailed comparison of all the three 
types of stem cells, embryonic stem cells (ESC), adult stem cells(ASC), 
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and induced pluripotent stem cells (iPSC), it can be concluded that 
hESCs are the unique source to be studied. Hence, for the project 
reported and discussed in this Master’s work, we only focus on the use 
of hESCs as a model towards osteogenic lineage.  
 
1.3 Osteogenesis from human embryonic stem cells 
 
To apply hESCs in bone engineering, it is of key importance to induce 
in-vitro differentiation of hESCs into osteoblast lineage which can 
further differentiate into osteoblasts. hESCs differentiation toward 
osteoblast lineage was first reported in 2003 [59]. Since then, 
numerous reports have been published for the successful direct 
generation of osteoblast lineage cells from hESCs [40-50]. At present 
stage, it is a daunting task to find out the regulating mechanisms that 
controls the process of in-vivo osteogenic differentiation. However, in 
contrast, in-vitro studies can offer a visible perspective on hESCs 
osteogenic differentiation, because it is relatively easier to characterize 
the molecules and manipulate the process. In order to obtain well 
differentiated osteogenic cell groups from hESCs, it is important to 
devise efficient protocols. Various protocols have been developed to 
enhance the efficiency of osteogenesis in-vitro, which also facilitates 




The most conventional approach of inducing differentiation is to culture 
hESCs in the presence of dexamethasone to induce differentiation 
towards osteogenic lineage, ascorbic acid to stimulate extracellular 
matrix (ECM) synthesis and β-glycerophosphate to promote 
mineralization [45]. To improve the differentiation efficiency of the 
above protocol, use of various additives has been reported till date. For 
instance, differentiation in the presence of restructured cell factors, 
growth factors and other chemicals are applied to mimic in-vivo 
microenvironment and induce differentiation, in order to achieve better 
purity and efficiency of the differentiation [46]. 
 
It would be essential to develop well-defined and efficient protocols for 
directing stem cell differentiation into the osteogenic lineage in-vitro. 
Conventional protocols to induce the differentiation of hESCs into 
osteogenic cells usually include the embryoid body stage. Osteogenic 
cells in the early developmental stage mainly originated from embryoid 
bodies (EBs). These three-dimensional cell spheroids mimic the early 
stages of embryonic development. As the EB-based differentiation is 
ineffective, an alternative method has been used to omit EB step 
during differentiation [60]. The progenitor cells are cultured in-vitro to 
increase their numbers, and then placed onto scaffolds with factors 
capable of stimulating osteogenic differentiation. After that, the cells 
are implanted into the skeletal defect. Recently, reports have focused 
on directing osteogenic differentiation of hESCs co-cultured with 
different cell groups [61]. Other alternative methods, include culturing 
 19 
the cells on ECM [62] and exposure to short periods of physical 
stimulation [63]. 
 
Three-dimensional culture system can mimic the differentiation 
environment in-vivo. However, in some previous studies, osteogenic 
differentiation of hESCs was also obtained in two-dimensional culture, 
and scaffolds were only applied as a carrier of transplantation [61, 64, 
65]. Several types of porous scaffolds have been selected to support 
in-vitro bone formation, such as ceramics polymers and composite 
materials. Employing phase separation techniques to synthesize three-
dimensional poleis (L-lactic acid), with the same size scale as type I 
collagen is a novel culture system for differentiation [64]. The 
advantages of this method are that it can avoid immune reactions to 
ECM and the problems of pathogen transmission. This architecture can 
be applied to both 2D and 3D scaffolds to culture hESCs for further 
differentiation [65]. 
 
Another approach to direct the osteogenic differentiation of hESCs 
would be to co-culture stem cells with different cell population e.g. 
periodontal ligament fibroblasts (PDLFs) [61]. Undifferentiated hESCs 
were seeded on the PDLF-covered coverslips. Compared to the 
spontaneous differentiation group, the co-culture group displayed 
enhanced osteogenic differentiation status and suggests that the PDLF 
is capable of inducing osteogenic differentiation of hESCs. 
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Conventionally, hESCs are cultured on mouse embryonic fibroblast 
layer. Attempts at eliminating feeder-layer involve use of ECM proteins 
like Matrigel for hESC culture. Most recently, an autologous feeder-free 
ECM has been reported to support long term xeno-free culture of 
hESCs [66]; The ECM was extracted from autologous fibroblasts of 
hESC, which is more suitable for expanding clinical-grade hESCs.  
 
Another approach for directing the osteogenic differentiation is physical 
stimuli [63]. This method indicates that a pathway of differentiation can 
be influenced by the application of short periods of cyclic mechanical 
strain, enhancing the osteogenesis and bone nodule formation in vitro. 
 
1.4    Green Fluorescent Protein  
 
Methods such as reverse transcriptase polymerase chain reaction (RT-
PCR), flow cytometry, immunocytochemistry, and histology have been 
reliably able to characterize stages of differentiation within the 
osteogenic lineage in-vitro and in-vivo. However, their application is 
restricted, as they do not allow online monitoring. As such, lineage 
specific promoter-driven expression of fluorescent proteins presents an 
innovative and advantageous strategy [67].  
 
Green fluorescent protein (GFP) is a 27-kDA protein that comes from 
the jellyfish Aequorea victoria, and is visible under excitation by laser, 
UV or blue light, emitting green light. [68, 69]. Taking advantage of 
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these characteristic, biologists have used GFP to mark various 
biological molecules or cell, and observe them through microscope 
under blue light illumination. This was simply unthinkable before this 
protein was discovered and used. This protein which completely 
changed the way of biological research was first obtained by 
separating it from a jellyfish Aequorea victoria existing in the Pacific 
Ocean. However, its utility as a tool for molecular biologists did not 
begin to be realized until 1992 when Douglas Prasher reported the 
cloning and nucleotide sequence of wtGFP [70]. In 1994, the lab of 
Martin Chalfie took GFP as a universal gene marker in biological 
technology, and utilized GFP in various organisms, and thus 
establishing GFP technology’s significant role in biological studies. The 
first significant leap forward of GFP technology is the multicolor 
fluorescent protein marking technology invented by Roger Y. Tsien [71].  
Nowadays, GFP and its variants has become a standardized gene-
marking/ cell-tracing tool.  
 
1.4.1 Application of Green fluorescent protein technology 
 
The role of transplanted human cells in the bone regeneration process 
was proven by the identification of green fluorescent protein and 
expression of human-specific nuclear antigen in osteocytes in newly 
formed bone. 
 
1. Molecule marking 
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As a new type of reporting gene, GFP has been utilized in many 
research fields of biology. Taking advantage of the unique 
luminescence mechanism, GFP can be used for protein tagging. The 
protein tagging uses the DNA recombination technology to combine the 
target gene and GFP gene as fusion gene followed by transfection into 
suitable cells. Following the transfection, the protein encoded by the 
target gene inside living cells can be observed by a fluorescent 
microscope.  
 
In 1996, it was first reported that Ehrdardt et al. took advantage of GFP 
characteristics to study the cellular location of a differentiation protein 
FtsZ [68]. Using GFP to test and measure the location of target protein 
has provided us a new method to more thoroughly observe some basic 
biological processes within cell. Besides being applied in marking and 
locating certain proteins, GFP are also extensively utilized to mark 
such cell organelles as cell skeleton, cell membrane, cell nucleus, etc. 
It was reported that Shi et al. combined GFP to the surface of 
Escherichia Coli cell membrane to mark proteins [69]. This research 
provided a new direction and method for future studies, and thus 
making GFP utilization for cross-discipline scientific research. 
 
2.  Screening and development of novel pharmaceutical compounds 
Many newly-developed optical analytic methods have begun to utilize 
living cells for screening and development of novel pharmaceutical 
compounds [70]. This technology is able to quickly find out and select 
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novel compounds from large quantities of chemical compounds. 
Because of GFP’s unique luminescence mechanism and high 
infiltration rate inside cells, GFP has a great potential in the field of 
examining and selecting medicines. 
 
3. Fusion antibody 
Because fusion antibody is characterized by the two features of being 
capable of combining with antigens and radiating fluorescence, this 
artificial molecule can be used as test agent for immunostaining and 
directly applied in flow cytometry, marking of immuno-fluorescence and 
testing of tumors etc [69]. 
 
4. Bio-sensor 
Protein engineering is used to design bio-transducers by combining 
one signal transduction molecule to another molecule. The first GFP-
based bio-transducer is Ca2+ transducer, which was put forth by 
Romoser and Miyawaki almost at the same time [70]. This type pf GFP 
transducer can be used to test various molecules, such as protein, 
nucleic acid, hormone, metal and other small molecule chemical 
compounds, which has a great potential of appliance in extensive fields. 
 
Briefly, due to our team member Mr. Zou Yu’s work, the GFP 
transfected technology has been used in human embryonic stem cells. 
The GFP transfected hESC cell lines including H1 and H9 have been 
established in A/P. Cao Tong’s stem cell laboratory, Oral Sciences, 
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Faculty of Dentistry, National University of Singapore. In this work we 
utilized these GFP expressing hESC cell lines to validate their 
osteogenic ability.  
 
Prior to the in-vivo application of GFP transfected hESC, it has to be 
tested whether GFP transfection influences the hESCs’ osteogenic 
differentiation potential and efficiency. Consequently, we hypothesize 
no significant difference between the osteogenic differentiation 
processes induced by the above-mentioned two types of cells. 
  
This study directly compared the in-vitro osteogenic capacity of 
















Chapter II   







2.1 Agents and culture media preparation 
 
2.1.1 Human embryonic stem cell culture  
 
The following methods are according to the protocols from WiCell 
Research Institute, University of Wisconsin-Madison, USA. 
 
2.1.1.1   Gelatin coating 
500ml endotoxin-free water was prepared in a sterile glass bottle. And 
then 0.5 grams porcine gelatin (G1890, Sigma) was added into the 
bottle. The solution was autoclaved for 30 minutes. After usage, the 
solution was stored at 4oC. 
 
2.1.1.2 Mouse embryonic fibroblasts culture media  
The culture medium used for expanding MEF cells was composed of  
high glucose DMEM (Sigma, St. Louis, MO, USA) and 10% fetal bovine 
serum (FBS, Hyclone, UT, USA). 
 
2.1.1.3 Human embryonic stem cells culture media (Wicell) 
 
The hESC medium was composed of the DMEM:F12 (Gibco, Life 
Technologies), 20% knockout serum replacement (Gibco) 
supplemented with 4 ng/mL β-FGF (Invitrogen), 1mM L-glutamine 
(Gibco) with 0.1mM β -mercaptoethanol (2-ME; Sigma-Aldrich) and 1% 
nonessential amino acid (NEAA; Gibco). The solution was added to a 
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filter flask (0.22μ m, Millipore) and filtered. Culture media was used 
within two weeks after preparation. 
 
2.1.1.4 Collagenase solution 
1mg/ml fresh collagenase solution was prepared before passage of 
hES cells. 1mg collagenase type IV (Invitrogen) was dissolved in 1ml 
DMEM: F12 solution (Invitrogen), and then filtered. 
 
2.2 Culture of H1 and H9 human embryonic stem cells 
NIH-registered H1 and H9 hESC lines were cultured and passaged 
strictly in accordance with the protocol of “Introduction to human 
embryonic stem cell culture methods” from WiCell Research Institute, 
University of Wisconsin-Madison, USA and as previously published 
[73]. 
 
2.2.1 Fluorescent labeling of H1 and H9 hESC  
The hESCs H1 and H9 were fluorescently labeled by established by 
members of A/P Cao Tong. Briefly, H1 & H9 -hESCs grown on mouse 
embryonic fibroblasts were single cell dissociated using accutase and 
transfected with a plasmid construct consisting of pAcGFP1-1 
backbone with pCAG-GFP promoter (Clontech) using X-tremeGENE 
HP DNA Transfection Reagent (Roche). The transfected H1-hESCs 
were seeded onto mouse embryonic fibroblast feeders and medium 
was supplemented with Y27632 (Inhibitor of Rho-associated protein 
kinase, ROCK; Stemgent) to aid cell survival and attachment. With 
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every passage colonies expressing GFP were manually selected and 
passaged to obtain hESC colonies with homogeneous expression of 
eGFP. These H1 & H9 -hESCs expressing GFP were cultured for more 
than 5 passages before using for further differentiation studies.  
 
2.2.2   Culture and passage of H1 and H9 embryonic stem cells 
 
The hESCs H1 and H9 lines were cultured and propagated following 
the Wicell protocols which are described as follows. Briefly, murine 
embryonic fibroblast cells were harvested from 12.5-day uteri of 
pregnant CF1 mice and cultured to passage 4. The P4 MEFs then 
were inactivated by 10 mg/mL mitomycin c for 2h. Approximately  
2×105 of inactivated MEF cells were seeded on the  0.1% gelatin-
precoated two six-well plates (Becton-Dickinson Inc., USA) incubated 
in humidified 5% CO2 incubator at  37°C for 24 hours before H1 and H9 
hESC seeding. Before seeding hESCs, the MEF culture media was 
removed and the MEF cell layer was washed with phosphate buffered 
saline (PBS, FirstBase, Singapore) three times and cultured on hESCs 
medium. Then H1 and H9 hESC cells were propagated on the 
inactivated MEF feeder on two 6-well culture plates in humidified 5% 
CO2 incubator at 37oC. The two plates were placed in incubator for 48 
hours. And the hESC culture media was changed daily. 
  
The cells were passaged every 5 to 6 days when cells were confluent. 
1ml collagenase solution was added to each well of the two 6-well 
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plates and incubated for 3 minutes. Clumps of cells were collected and 
centrifuged at 200g for 5mins. The supernatant was removed and the 
cell pellet was seeded on the inactivated MEF feeder and cultured in 
2.5ml of hESC culture media for further passages or differentiation.  
 
2.3 Culture and passage of Green fluorescent protein transfected 
human embryonic stem cells. 
 
H1GFP+ and H9GFP+ hESCs were passaged similar to H1 and H9 hESCs, 
except the following additional steps. To ensure that hESC colonies 
had homogenous GFP expression, those colonies that expressed GFP 
were manually selected and passaged to obtain hESC colonies with 
homogenous expression of GFP.  
 
2.4 Osteogenic differentiation of hESCs 
 
2.4.1 Preparation of culture media for osteogenesis 
 
Osteogenic differentiation media was composed of DMEM high 
glucose (Sigma-Aldrich), 2 ×10-4 M ascorbic acid, 10% FBS (Fetal 
bovine serum; Biowest) supplemented with 10-7M dexamethasone and 
10mM β-glycerophosphate (Sigma-Aldrich). The working media was 
stored at 4°C and used within two weeks after preparation. 
 
2.4.2 Procedure for osteogenic differentiation 
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H1, H1GFP+, H9 and H9GFP+ hESC colonies dissociated from the feeder 
layers by treatment with 2mg/mL collagenaseIV for 30min, respectively. 
Floating colonies were collected and split into smaller colonies through 
vigorous pipetting in the osteogenic medium. The colonies were then 
seeded into 12-well BioFlex plates coated with type I collagen (Flexcell 
International) and cultured in the osteogenic medium at 37oC in a 
humidified atmosphere of 5% CO2/95% air for 14 to 21 days. Colonies 
were incubated for 21 days with media being changed every third day. 
Four groups were established: osteogenesis of H1 cell line, 
osteogenesis of H1GFP+ cell line, osteogenesis of H9 cell line, and 
osteogenesis of H9GFP+. 
 
2.4.3 Characterization of osteogenesis 
 
2.4.3.1 Alizarin red staining 
 
Alizarin red staining is an effective method used to examine the 
presence of calcium deposition during osteogenic differentiation. After 
21 days of osteogenesis, alizarin red staining was performed to mark 
the matrix deposition.  
 
In this study, on day 21 of osteogenic differentiation, the differentiated 
cells were washed with PBS (Ca2+/Mg2+free) for three times and fixed 
with 4% formaldehyde (sigma) for 20 minutes at room temperature. 
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The working solutions were then aspirated. The plates were then 
washed with double distilled de-ionized water for three times and 
stained with 500ul of 2% alizarin red working solution in each well for 5 
minutes at room temperature in dark. The plates were washed with 
distilled de-ionized water thoroughly. The plates were then air dried 
and formation of crystalline hydroxyapatite and Ca2+ was visualized 
using inverted light microscope. 
 
2.4.3.2   Immunostaining 
 
Cell cultures were fixed with 0.3mL 4% paraformaldehyde (Sigma) for 
15 minutes at room temperature (RT), phosphate-buffered saline (PBS) 
washed for three times. Permeabilization for 10 minutes with 0.3 ml 
0.2% Triton X-100 in phosphate-buffered saline (PBS), and blocked for 
1 hour with 5% goat serum and 2% BSA (Sigma-Aldrich) in PBS. The 
primary antibody was then incubated with the cells at 4℃ overnight. 
The primary antibodies include rabbit anti-human Col-I (AbD Serotec); 
donkey anti-goat Runx 2(AbD Serotec); mouse anti-human osteocalcin 
(AbD Serotec). After 3 washes with 1X PBS, then the cultures were 
incubated with Alexa Flour 594-conjugated secondary antibodies, goat 
anti-rabbit IgG (100X dilution PBS with 0.1%BSA, Molecular Probes, 
Invitrogen) for 20 minutes at room temperature. After three washes 
with PBS, DAPI was added 10 minutes before the last three washes 
with PBS and examined by fluorescent microscopy. The cultures were 
then washed with PBS before fluorescent microscopy.  
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2.4.3.3 Collagen staining 
 
Cell cultures were washed three times with PBS and 500mL of the 
Sircol dye reagent added to 3 wells in different groups respectively. 
Plates were gently agitated for 1 hour followed by chilled acid-salt wash 
reagent washed another three times to remove unbound dye. 500 µl of 
alkaline reagent was added to each well to extract bound dye for 10 
minutes with gentle agitation. Absorbance of 200µl of the extracted dye 
solution was taken at 555nm with an infinite 200 microplate reader 
(Tecan). 
 
2.4.3.4 Total collagen (matrix) 
 
A Sircol soluble collagen assay kit (Biocolor) was applied to quantify 
total collagen synthesis. Briefly, cell cultures were washed three times 
with PBS and 500mL of the Sircol dye reagent added to each well. To 
remove unbound dye, plates were gently agitated for 1 hour followed 
by another three washes with chilled acid-salt wash reagent. 500 µl of 
alkaline reagents was then added to each well for 10 minutes with 
gentle agitation to extract bound dye. Absorbance of 200mL of the 
extracted dye solution was measured at 555nm with an infinite 200 
microplate reader (Tecan).  
 
2.4.3.5 Total cell number, MTS 
 33 
 
MTS assay is a laboratory colorimetric assay that measures the activity 
of mitochondrial activity. Enzyme reductase from mitochondria converts 
yellow MTT into purple color formazan. CellTiter96® Aqueous Solution 
Cell Proliferation Assay kit (Promega) was used for this experiment. 
MTS reagent was added to the selected wells of different groups in the 
concentration of 1:5 (MTS reagent: medium vol/vol), 120mL of the MTS 
reagent (Promega) was mixed with 600 mL of media and incubated at 
37°C in humidified atmosphere with 5% CO2 for 4 hours. The 
absorbance was read at 490nm using Infinite® 200 microplate reader 
(Tecan group. Männedorf, Switzerland). 
 
2.4.3.6 PCR assay 
 
Total mRNA was extracted using RNeasy Mini Kit (Qiagen, German) 
on differentiated cells on day 21. Strictly following manufacturer’s 
instructions, total mRNA was extracted and quantified by Nanodrop 
(Nanodrop technologies, Wilmington, DE). cDNA was generated from 
500ng of RNA using iScript TM cDNA synthesis kit (Biorad, Hercules, 
CA). The PCR was performed using Mycycler, PCR thermal cycler 
(Biorad). Samples which were collected from four groups were 
denatured thoroughly at 95°C for 5 minutes, in each cycle of 35 cycles. 
The samples were then denatured at 95°C for 30 seconds, followed by 
specific annealing temperature for different genes from 55-65°C for 45 
seconds, and double strand DNA synthesis at 72°C for 1 minute, and 
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ended with extension at 72°C for 5 minutes. β-actin was used as 
control to normalize PCR reactions. PCR products were further loaded 
on 2% agarose gel electrophoresis with ethidium bromide staining. 
Bands were visualized using Universal Hood Light Imaging System 
(Biorad segrate, Milan, Italy).  
 
Gene Primer sequence Annealing 
Temp 








Osteocalcin F: ATGAGAGCCCTCACACTCCTC  
R: GCCGTAGAAGCGCCGATAGGC 
61°C 




2.4.3.7 Alizarin red extraction assay 
 
The hESCs differentiated towards osteogenic lineage were fixed with 
4% paraformaldehyde for 20 minutes and stained with 1% Alizarin Red 
S (pH 4.2, Sigma-Aldrich) for 20 minutes to detect calcified 
extracellular matrix, the stain was extracted with 100 µl/well of 10% 
cetylpyridinium chloride in 10 mM sodium phosphate buffer (pH 7.0) for 
15 minutes. The absorbance of the solution was read at 562nm using 
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Infinite® 200 microplate reader (Tecan group. Männedorf, Switzerland). 
 
2.4.3.8 Statistical analysis 
 
Statistical analyses were performed using an SPSS software package 
(IBM). Differences between groups were evaluated by one way 
ANOVA with the level of significance set at p < 0.05. Results of the 























3.1 Osteogenic differentiation of normal and GFP-expressing 
hESCs 
H1GFP+-hESCs were grown on MEF and culture medium(Figure 3.1 A), 
Phase-contrast image of an expanding H1GFP+-hESCs  colony shows a 
clear boundary from surrounding MEF feeder cells. H1GFP+-hESCs 
displayed fluorescent characteristic when under fluorescent microscope 
(Figure 3.1 B). 
 
Dissociated colonies from different hESC groups were plated and 
differentiated in osteogenic medium for 21 days. Generally, osteogenic 
differentiation ability is assessed after 14 to 21 days of differentiation 
(48). Based on previous studies, we have compared the osteogenic 
differentiation ability of H1, H9, H1GFP+, and H9GFP+ cells after 21 days 
of osteogenic differentiation. For all four groups, heterogeneous cell 
populations with various morphologies could be observed after 3 days’ 
differentiation (Figure 3.2 A, B). Within one week, differentiated cells 
started to aggregate and formed small semi-transplant nodules. 
Obvious nodules formation could be observed in the differentiating 
cells after 12 days (Figure 3.2 C, D) and they continued to expand 
during the 21 days’ differentiation (Figure 3.2 E, F). Notably, 
differentiation in osteogenic medium did not significantly affect the 







Figure 3.1 A H1GFP+-hESCs cultured on the inactivated MEF feeder  
B H1GFP+-hESCs under fluorescent microscope 
Green: Green Florescent protein  







Figure 3.2 A, B Osteogenic differentiation derived from H9 hESCs in 
day 7 C, D Osteogenic differentiation derived from H9 GFP+-hESCs in 
day 12 under fluorescent microscope. E, F Osteogenic differentiation 
derived from H1 GFP+-hESCs in day 21 Green: Green Florescent protein 
 
 
3.2   Expression of osteogenic genes in differentiated cells 
In order to confirm the osteogenic differentiation of the hESC derived 
cells, expression of osteogenic related genes were analyzed in all 
groups by reverse transcription PCR after 21 days’ differentiation. 
Results showed that all of the tested osteogenic genes, including 
collagen, osteocalcin (OC) and Alkaline phosphatase (ALP) were 
strongly expressed in all groups of osteogenic differentiated cells 
(Figure 3.3), which suggested these cells have possessed similar gene 




Figure 3.3   RT-PCR shows the expression osteogenic-related genes 
(Collagen 1, Osteocalcin and ALP) by H1, H9, H1GFP+, and H9GFP+ cells 




3.3   Immunostaining of osteogenic markers 
 
Immunostaining was performed to further detect the osteogenic related 
markers in protein level after 21 days’ differentiation. Four markers, 
Collagen I, Osteoclacin, RunX2 and ALP, were selected to indicate the 
osteogenic differentiation of hESC derived cells. Presence of all of the 
four markers could be detected in four groups of differentiated cells; 
However, positive staining mainly distributed in the areas that contain 
multiple layers of cells or cell clumps, while markers expression in 
areas containing monolayer cells were comparatively limited (Figure 
3.4- Figure 3.11). Co-staining of Collagen I and Osteoclacin in H1-
hESC derived cells showed that collagen I had wider distribution and 
stronger staining than Osteoclacin in both GFP expressing or non-
expressing cells (Figure 3.6, Figure 3.7). Similar results could also be 
observed in the H9-hESC derived cells (Figure 3.10, Figure 3.11). In 
terms of co-staining of RunX2 and ALP, ALP seemed to have wider 
distribution than RunX2, in the H9GFP+-hESC and H1GFP+-hESC; 
however, this difference was not obvious in the H1-hESC derived cells 
(Figure 3.4, 3.5). In H9 derived cells, stronger staining of ALP also 
could be found in H9GFP+-hESC (Figure 3.8, 3.9). Notably, although co-
staining results showed these markers were highly co-localized in cell 
clumps, but some portions of the cells still only expressed one of the 
markers, which suggested the cell clumps were composed of 



















Figure 3.4 Representative photomicrographs show the expression of 
RunX2 (Red) and ALP (Green) by H1-hESC derived osteogenic cells 
after 21 days of osteogenic differentiation. The nuclei were 
counterstained with DAPI (blue), and all the three color channels 
merged to examine the co-localization of these two bone matrix 
components. Scale bars represent 500 µm
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Figure 3.5 Representative photomicrographs show the expression of 
RunX2 (Red) and ALP (Green) by H1 GFP+-hESC derived osteogenic 
cells after 21 days of osteogenic differentiation. The nuclei were 
counterstained with DAPI (blue), and all the three color channels 
merged to examine the co-localization of these two bone matrix 
components. Scale bars represent 500 µm.
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Figure 3.6: H1-hESCs osteodifferentiated (21 days) OC + COL1  
     












Figure 3.6 Representative photomicrographs show the expression of 
COL1 (Red) and OC (Green) by H1-hESC derived osteogenic cells 
after 21 days of osteogenic differentiation. The nuclei were 
counterstained with DAPI (blue), and all the three color channels 
merged to examine the co-localization of these two bone matrix 
components. Scale bars represent 500 µm. 
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Figure 3.7 Representative photomicrographs show the expression of 
COL (Red) and OC (Green) by H1 GFP+-hESC derived osteogenic cells 
after 21 days of osteogenic differentiation. The nuclei were 
counterstained with DAPI (blue), and all the three color channels 
merged to examine the co-localization of these two bone matrix 
components. Scale bars represent 500 µm. 
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Figure 3.8 Representative photomicrographs show the expression of 
RunX2 (Red) and ALP (Green) by H9 GFP+-hESC derived osteogenic 
cells after 21 days of osteogenic differentiation. The nuclei were 
counterstained with DAPI (blue), and all the three color channels 
merged to examine the co-localization of these two bone matrix 
components. Scale bars represent 500 µm. 
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Figure 3.9 Representative photomicrographs show the expression of 
RunX2 (Red) and ALP (Green) by H9 -hESC derived osteogenic cells 
after 21 days of osteogenic differentiation. The nuclei were 
counterstained with DAPI (blue), and all the three color channels 
merged to examine the co-localization of these two bone matrix 





















Figure 3.10 Representative photomicrographs show the expression of 
COL1 (Red) and OC (Green) by H9-hESC derived osteogenic cells 
after 21 days of osteogenic differentiation. The nuclei were 
counterstained with DAPI (blue), and all the three color channels 
merged to examine the co-localization of these two bone matrix 
components. Scale bars represent 500 µm. 
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Figure 3.11 Representative photomicrographs show the expression of 
COL1 (Red) and OC (Green) by H9 GFP+-hESC derived osteogenic cells 
after 21 days of osteogenic differentiation. The nuclei were 
counterstained with DAPI (blue), and all the three color channels 
merged to examine the co-localization of these two bone matrix 











3.4   Alizarin red staining and quantification 
To detect the mineralization of the osteogenic differentiated cells, 
alizarin red staining was performed in four groups of differentiated 
hESCs after 21 days. In all groups, mineralization with red staining 
could be observed; moreover, most of the stained areas highly 
overlapped with nodule formation areas, which suggested cell 
aggregation and nodule formation promote mineralization of the 
differentiated cells (Figure 3.12, Figure 3.13). However, quantification 
of alizarin red staining by extracting the stained dyes revealed that 
although GFP expression did not significantly influence the 
mineralization ability of hESC in both H1 and H9 cell lines, the dye 
absorbance of H9 derived cells (both GFP expressing or non-
expressing) were significantly higher than H1 derived cells (Figure 
3.14, Figure 3.15), which implied that osteoblasts differentiated from 
H9 might have stronger mineralization ability that those derived from 
H1. The alizarin red extraction assay reveals differences in calcium 
deposits after osteogenic differentiation of different cells. In particular, 
the GFP-transfected cells have lower levels of calcium deposition. The 
difference may be attributed to individual cell differences in 
osteodifferentiation ability. However, detailed in-vivo studies are 
needed to ascertain the significance of such differences. 
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Figure 3.12 Alizarin Red staining of H1-hESCs osteodifferentiated 
cells  
 
A. H1-hESCs osteodifferentiated cells 
 
B. H1GFP+-hESCs osteodifferentiated cells 
Figure 3.12 Representative photomicrographs show the formation of 
calcium deposits within osteogenic differentiated cells after Alizarin red 
staining of H1 (A) and H1GFP+ (B) cells after 21 days of osteogenic 
differentiation. Scale bars on the left figures represent 500 µm and 
those on the right 200 µm 
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Figure 3.13 Alizarin Red staining of H9-hESCs osteodifferentiated 
cells.  
 
A. H9-hESCs osteodifferentiated cells 
 
 
B. H9GFP+-hESCs osteodifferentiated cells 
Figure 3.13 Representative photomicrographs show the formation of 
calcium deposits within osteogenic differentiated cells after Alizarin red 
staining of H9 (A) and H9GFP+ (B) cells after 21 days of osteogenic 
differentiation. Scale bars on the left figures represent 500 µm and 











Figure 3.14 Semi-quantitative comparison of formation of calcium 
deposits within osteogenic differentiated cells after Alizarin red 
extraction assay of H1 and H1GFP+ cells after 21 days of osteogenic 
differentiation.  
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Figure 3.15 Semi-quantitative comparison of formation of calcium 
deposits within osteogenic differentiated cells after Alizarin red 
extraction assay of H9 and H9GFP+ cells after 21 days of osteogenic 





3.5 Total collagen staining and quantification  
 
To further investigate whether GFP expression or cell line difference 
will significantly affect the extracellular matrix (ECM) production in the 
differentiated cells, we continued to analyze the total collagen 
production after 21 days’ differentiation. Results showed that all four 
groups were able to produce collagens that were deeply stained in red 
color. Interestingly, similar to the distribution of alizarin red staining, the 
collagen staining also highly co-localized with the cell aggregation and 
nodules formation areas. This finding suggested these areas were not 
only highly mineralized but also generated higher amount of collagens 
than other regions. To further compare the ECM production in different 
groups, the collagen-staining dyes were extracted and the absorbance 
was compared. Surprisingly, results indicated that although H9GFP+-
hESC derived osteoblasts did not showed higher collagen production 
than H1 derived cells, H9-hESC derived osteoblasts generated 
markedly higher amount of collagens than all other groups, which 
suggested GFP expression might actually down-regulate collagen 
production in H9 derived cells. On the other hand, H1GFP+-hESC 
derived cells did not obviously influence the collagen production 










Figure 3.16: Representative photomicrographs show collagen staining 
of osteogenic differentiated cells of H1 and H1GFP+ cells after 21 days 
of osteogenic differentiation. Scale bars on the left figures represent 
















Figure 3.17: Representative photomicrographs show collagen staining 
of osteogenic differentiated cells of H9 and H9GFP+ cells after 21 days 
of osteogenic differentiation. Scale bars on the left figures represent 










Figure 3.18: Quantification of total collagen secretion at day 21 
 
 
Figure 3.18 Semi-quantitative comparison of collagen secretion of H1, 
H9, H1GFP+ and H9GFP+ cells after 21 days of osteogenic differentiation.  
 
 
3.6   MTS assay and cell viability 
 
In order to evaluate whether GFP expression in hESC derived cells will 
affect cell viability after differentiation, we performed MTS assays in the 
four groups of cells to compare their viabilities.  Surprisingly, we found 
that H1GFP+-hESC derived cells even had higher cell viability than the 
H1-hESC derived cells (P<0.05). However, GFP expression did not 





Figure 3.19: MTS assay for total cell number at day 21 
 
Figure 3.19 Comparison of cell viability of H1 and H9 (gray bars); 
H1GFP+ and H9GFP+ (green bars) cells after 21 days of osteogenic 













Discussion and Conclusion  
 60 
So far, the clinical treatment applied to restore bone diseases caused 
by inborn bone defects or damages cannot meet patients’ demands 
due to limitations such as lack of grafting material, compatibility 
problems of the implanted material, and shortage of cells with 
reparative potential.  
 
The emergence of stem cell and bone tissue engineering brought new 
hopes to clinical therapeutic treatment of bone diseases. Because stem 
cells have innate potential for direct differentiation and are capable of 
being manipulated on a large scale for tissue regeneration, stem cells 
have attracted lot of attention from relevant research field and been 
considered to be the best candidate cell sources for such bone 
therapies in recent years [71-73]. 
 
Because pluripotent hESCs are able to lead to unlimited numbers of 
specialized cells existing in the bone, they are deemed to be the most 
suitable for bone engineering. In addition, in the treatment of bone 
diseases, especially transplanting bone tissue on large scale for bone 
restoration, application of hESCs can solve such problems as tissue 
compatibility, safety, etc. [74] 
 
However, great attention must be paid to possible side effects of the 
graft, and a thorough understanding of the interactions between 
transplanted cells and host tissues should be reached, even at the 
preclinical level [3]. In-vitro research provides an effective platform for 
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studying the above-mentioned research fields and lays a foundation for 
more effective clinical application in the future. 
 
Osteogenic differentiation potential of hESCs in-vitro has been 
investigated in recent years. However, until recently, the very first case 
of using bone cell progenitors derived from hESCs grown compact 
bone tissue on a sufficient scale for repairing centimeter-sized defects 
was realized in experiments on mice [75]. This provides a proof of 
principle that tissue-engineering protocols can be successfully applied 
to hESC progenitors to grow bone grafts for use in basic and 
translational studies. 
 
An important early step before at-large application of bone tissue 
engineering technology in clinical practices is the differentiation of 
hESCs into cells of the osteoblast lineage. Such in-vitro experiments as 
optimizing protocols for culture and differentiation of hESC derived 
bone cells, enhancing differentiation efficiency, etc. are of essential 
importance to guiding future clinical applications.  
 
In order to study the effectiveness of stem cells in clinical therapy, 
studies are conducted to track their development after transplantation. 
Because It is ideal to monitor each and every cell’s development [76], it 
is reasonable to devise innovative techniques to label cells for 
subsequent monitoring of the presence and persistence of cells after 
transplantation [77].  
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Whether the protocol to detect the label is compatible with other 
analyses, such as immunohistochemical determination of the 
phenotype of grafted cells; and whether the label is stably incorporated 
or has the potential to transfer to endogenous cells. The gene-based 
reporter green fluorescent protein (GFP) fulfills all these criteria and is 
therefore an ideal marker for labeling cells. 
 
Fluorescent protein reporters such as GFP are advantageous also 
because GFP fluorescence can be visualized directly, without further 
processing [78]. In utilizing GFP for tracking transplanted cells，GFP 
also has many other advantages, including that it is constitutively 
fluorescent and so is readily detected when under the control of a 
constitutive promoter, it has a high fluorescence yield, and it is resistant 
to photo bleaching. GFP transfected technology as an optical imaging 
method used to track how stem cells incorporate and regenerate 
themselves in-vivo over time. It can identify and monitor the 
transplanted donor cells in the initial phase after transplantation 
because donor cell homing is a rapid process in the host environment 
[79]. 
However, utilizing markers like CFDA-SE for labeling transplanted cells 
is associated with progressively dilution when cells divide, either in-
vitro or in-vivo leading to fading of the fluorescent marker. In order to 
solve this problem, our laboratory team transfected hESCs with GFP. 
No matter in what direction the induced cells differentiate, green 
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fluorescence can be expressed continuously, constituting a very 
effective method of marking cells in-vivo in the future. Use of GFP 
transfected hESC for the in-vivo studies not only helps us to detect 
hESC-derived cells from the tissue of the host after transplanting but 
also helps us to understand the development of osteoblast cells that 
constitute the bone and its functions [80]. 
 
The first step of in-vivo application of GFP transfected hESC is to test 
whether GFP transfection influences the osteogenic differentiation 
potential and efficiency of hESCs. Therefore, it is hypothesized that 
there is no significant difference between the osteogenic differentiation 
processes induced by the above-mentioned two types of cells. 
 
In this study we have directly compared the in-vitro osteogenic capacity 
of osteogenic cells derived from normal hESCs and GFP transfected 
hESCs.  
 
H1 and H9 hESC lines were treated using cell culture protocols known 
to induce osteogenic differentiation in-vitro. The treatment conditions 
used were similar to those used in previous studies of hESC derived 
osteogenic differentiation [81]. Previous research from this laboratory 
has shown that hESCs cultured in a cocktail of dexamethasone, 
ascorbic acid, and β -glycerophosphate formed morphologically distinct 
nodule-like structures containing osteogenic cells. From the analysis of 
the results, it can be found that differentiation in osteogenic medium did 
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not significantly affect the visualization of GFPs in both H1 and H9 
hESC-differentiated cells. 
 
hESC differentiation into osteoblasts can be defined into three phases, 
namely the proliferation phase, the matrix deposition phase and the 
mineralization phase [82]. Osteogenic cells were identified based on 
the biomarkers ALP, Osteocalcin, RunX2 and COL I for 
immunocytochemical staining. Bone nodule formation, and two 
histochemical staining: alizarin red staining and collagen staining. In 
addition, we quantified the size of bone nodules as an indirect measure 
of the number of osteoprogenitors within our cultures. MTS assay and 
alizarin red extraction are also performed to evaluate whether GFP 
expression in hESC derived cells will affect cell viability after 
differentiation. 
 
The expression of osteogenic related genes osteocalcin (OC), alkaline 
phosphatase (ALP) including collagen were strong in all groups of 
osteogenic differentiated cells by reverse transcription PCR after 3 
weeks’ differentiation. The results suggested H1GFP+-hESC and H9GFP+-
hESC derived osteogenic sells have possessed similar gene 
expression profile as osteoblasts from H1-hESC and H9-hESC 
 
Upon differentiation, immunocytochemical staining for osteocalcin 
(Green) and type I collagen (Red), RunX2 (Red) and ALP (Green) was 
performed to examine the colocalization of these four bone matrix 
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components in the control group. The result presents that all of the four 
markers could be detected in four groups of differentiated cells. 
 
In all groups, mineralization with red staining could be observed. 
Moreover, most of the stained areas highly overlapped with nodule 
formation areas, which suggested cell aggregation and nodule 
formation promote mineralization of the differentiated cells. 
 
At day 21 confluent culture, the MTS assay showed that GFP did not 
result in any significant difference in cell proliferation and total cell 
number among four groups.  
 
The total collagen results showed that all four groups were able to 
produce collagens that were deeply stained in red color. This suggests 
that GFP expression or cell line difference did not significantly affect 
the extracellular matrix (ECM) production in the differentiated cells. 
Additionally, similar to the distribution of alizarin red staining, the 
collagen staining also highly co-localized with the cell aggregation and 
nodules formation areas. This finding suggested these areas were not 
only highly mineralized but also generated higher amount of collagens 
than other regions.  
 
To further compare the ECM production in different groups, the 
collagen-staining dyes were extracted and the absorbance was 
compared. Result suggested GFP expression in H1 derived cells did 
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not obviously influence the collagen production while GFP expression 
might actually down-regulate collagen production in H9 derived cells.  
 
This is first report to compare the capacity of osteogenic differentiation 
among different linage derived hESC cells with or without GFP 
expression. In this experiment, although H9 cell line shows a slightly 
higher total collagen deposition in the extracellular matrix compared 
with H1 cell line at the end of the differentiation, cells in all four groups 
were able to normally produce collagen type I, alkaline phosphatase 
and osteocalcin after osteogenic induction, regardless of GFP 
expression by H1 or H9-hESC-derived cells.  
In conclusion, this investigation has demonstrated that the expression 
of osteogenesis markers and osteoblast-specific markers indicated that 
the osteogenesis of H1GFP+-hESC and H9GFP+-hESC were not affected 
by GFP transfection.  The results have demonstrated the feasibility and 
the reliability of lineage tracking via tagging hESCs with GFP in the 
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